Conference
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium
Abstract
5093
Authors
Sridhar SS; Hotte SJ; Mackenzie MJ; Kollmannsberger C; Haider MA; Pond GR; Chen EX; Srinivasan R; Ivy SP; Moore MJ
Volume
25
Pagination
pp. 5093-5093
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2007
DOI
10.1200/jco.2007.25.18_suppl.5093
Conference proceedings
Journal of Clinical Oncology
Issue
18_suppl
ISSN
0732-183X